Blueprint
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 8,
2020
Edesa Biotech, Inc.
(Exact Name of Registrant as Specified in its Charter)
British Columbia, Canada
|
|
001-37619
|
|
N/A
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
100 Spy Court
Markham, Ontario, Canada L3R 5H6
|
(Address
of Principal Executive Offices)
|
(289)
800-9600
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name of
exchange on which registered
|
Common
Shares
|
EDSA
|
The
Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging
growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 8.01. Other Events
On January 8, 2020, Edesa Biotech, Inc. (the “Company”)
closed its previously announced registered direct offering of
1,354,691 common shares, no par value (the “Common
Shares”) and concurrent private placement of Class A Purchase
Warrants to purchase an aggregate of up to 1,016,036 Common Shares
and Class B Purchase Warrants to purchase an aggregate of up to
677,358 Common Shares. The Company expects to receive aggregate
gross proceeds in the offering of approximately $4.36 million,
before deducting fees to the placement agent and other estimated
offering expenses payable by the Company. Following the closing,
the Company has 8,859,159 Common Shares issued and
outstanding.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Edesa
Biotech, Inc.
|
|
|
|
Date:
January 8, 2020
|
By:
|
/s/
Kathi Niffenegger
|
|
Name:
|
Kathi
Niffenegger
|
|
Title:
|
Chief
Financial Officer
|